RESEARCH TRIANGLE PARK, NC – (BUSINESS WIRE) – Asensus Surgical, Inc. (NYSE American: ASXC), a medical system firm that’s digitizing the surgeon-patient interface to usher in a brand new period in Efficiency-Guided Surgical procedure ™, at present introduced the Non-public Healthcare Establishment Railway Scientific Hospital (RZD) Drugs of Rostov-on-Don (“RZD Drugs”), primarily based in Rostov, Russia, has began its Senhance® Robotic Surgical procedure program after buying a Senhance Surgical System.
“We’re excited to convey Senhance to such a prestigious, future-oriented establishment. RZD Drugs hosts a excessive quantity, multidisciplinary normal surgical procedure division that Senhance can use in a wide range of procedures, ”mentioned Anthony Fernando, President and CEO of Asensus Surgical. “We’re excited to see hospitals in Russia introduce Senhance and we look ahead to working with others within the area sooner or later.”
Asensus Surgical’s expertise platform, Senhance Surgical System, is the primary digital laparoscopic platform of its type to make use of superior intelligence to ship unmatched efficiency and affected person outcomes by machine studying. Senhance goes past the everyday surgical robotic programs and presents surgical security by haptic suggestions, eye monitoring digital camera management and 3D visualization and is the primary platform to supply 3mm devices (the smallest instrument out there worldwide on a robotic surgical platform) . . Senhance’s surgical system is powered by the Clever Surgical Unit ™ (ISU). The ISU permits a surgeon to machine imaginative and prescient management of the digital camera by responding to instructions and recognizing particular objects and places within the surgical subject, and permits a surgeon to vary the visualized subject of view by transferring their devices.
“In our high-volume normal surgical procedure division, we deal with delivering the perfect outcomes to our sufferers utilizing probably the most superior surgical applied sciences out there,” mentioned Professor Aleksandr Khitharyan, MD, AG, head of the overall surgical procedure division at RZD Drugs . “Finally, our purpose is to get sufferers again to their on a regular basis lives as shortly as attainable. Senhance’s broad applicability to a wide range of surgical procedures and its capacity to supply prime quality, reproducible outcomes whereas decreasing the invasiveness of the procedures will allow us to realize our purpose. ”
About RZD Drugs
The RZD Drugs was based in 1911 and is now a multidisciplinary medical facility that gives medical care in numerous areas. At the moment there are inpatient departments of the hospital with 535 beds in two territories of Rostov-on-Don and Bataisk. The hospital has a cardiovascular surgical procedure, urology, gynecology, neurosurgery and normal surgical procedure division that present high-tech medical care.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the surgeon-patient interface to usher in a brand new period in performance-guided surgical procedure by unlocking surgeons scientific intelligence to allow persistently superior outcomes and a brand new commonplace of surgical procedure. This builds on the muse of digital laparoscopy with the Senhance Surgical System powered by the Clever Surgical Unit (ISU) to enhance surgeon management and scale back surgical variability. With the introduction of machine imaginative and prescient, augmented intelligence, and deep studying capabilities all through the surgical expertise, we intend to holistically deal with the present scientific, cognitive, and financial deficiencies that drive surgical outcomes and value-based healthcare. Discover out extra about performance-guided surgical procedure and digital laparoscopy with the Senhance Surgical System right here: www.senhance.com. Now out there on the market within the US, EU, Japan, Russia, and choose different international locations. A full checklist of utility areas will be discovered at: www.senhance.com/indications. Extra info is on the market at www.asensus.com.
This press launch incorporates statements concerning the Senhance Surgical System and RZD Drugs beginning a program with the Senhance System. These statements and different statements relating to our future plans and targets represent “forward-looking statements” inside the that means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 and are meant to advertise the secure haven of. qualify legal responsibility established by the Non-public Securities Litigation Reform Act of 1995. Such statements are topic to dangers and uncertainties which can be typically tough to foretell, past our management, and that would trigger outcomes to vary materially from expectations, and embody whether or not RZD Drugs will be capable of use the Senhance Surgical System within the occasion of a Use a mess of procedures, whether or not Asensus can work with others in Russia and the encircling area sooner or later, and whether or not the Senhance Surgical System will allow RZD Drugs to realize its purpose of delivering prime quality, reproducible outcomes concurrently the invasiveness of the procedures to scale back. For a dialogue of the dangers and uncertainties referring to the corporate’s enterprise, please see our filings with the Securities and Alternate Fee (SEC), together with our Annual Report on Kind 10-Ok for the yr ended December 31, 2020 filed with the SEC was filed on March 11, 2021 and our different filings we’re making with the SEC. You might be cautioned to not place undue reliance on these forward-looking statements, that are primarily based on our expectations as of the date of this press launch and converse solely as of the date of this press launch. We assume no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or for some other purpose.